Harbin Pharmaceutical announced on October 11 that the company recently received a case filing notice and a detention notice from the relevant supervisory committee regarding its director and president Lu Chuanyou. Harbin Pharmaceutical said it has made proper arrangements for related work, and that the chairman, other directors, and other senior managers are all performing their duties normally. The board of directors is operating normally, and production and operations are normal. The matters in the announcement will not have a material impact on the company's production, operations, or management. According to Harbin Pharmaceutical's 2025 annual report, Lu Chuanyou is 64 years old. He previously served as chief engineer, executive deputy factory director, factory director, and party secretary of Harbin Pharmaceutical Group No. 6 Pharmaceutical Factory, party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd., and vice president and senior advisor of the company. He currently serves as a member of the company's party committee, a director of the 10th board of directors, a member of the board's strategy and sustainable development committee, and president. In 2025, he received a salary of 2.9668 million yuan. Harbin Pharmaceutical focuses on the pharmaceutical and health industry, mainly engaged in pharmaceutical research and development, manufacturing, wholesale, and retail. In the first half of this year, the company achieved operating revenue of 8.296 billion yuan, an increase of 2.10 percent year on year. Net profit attributable to shareholders of the listed company was 410 million yuan, an increase of 57.99 percent year on year. Net profit attributable to shareholders of the listed company after deducting non-recurring items was 355 million yuan, an increase of 45.39 percent year on year. Basic earnings per share were 0.1629 yuan.
Harbin Pharmaceutical Group Co LtdPresident and director Lu Chuanyou placed under investigation and detained by supervisory committee, a legal/regulatory action against a top executive.
